Serum Angiotensin-Converting Enzyme Has a High Negative Predictive Value in the Investigation for Systemic Sarcoidosis

2018 ◽  
Vol 194 ◽  
pp. 82-87 ◽  
Author(s):  
Rachael L. Niederer ◽  
Ahmed Al-Janabi ◽  
Sue L. Lightman ◽  
Oren Tomkins-Netzer
1981 ◽  
Vol 27 (4) ◽  
pp. 530-534 ◽  
Author(s):  
K W Ryder ◽  
S J Jay ◽  
S A Jackson ◽  
S R Hoke

Abstract Although serum angiotensin converting enzyme (EC 3.4.15.1) activity has generally been shown to be increased in patients with sarcoidosis, considerable variation in the diagnostic usefulness of this test has been reported. We investigated the possibility that this variation may be the result of inhibition of the widely used spectrophotometric assay by various substances. We also prospectively examined the predictive value of measurements of this enzyme in serum from 100 patients being evaluated for sarcoidosis. The following did not significantly affect the results: storage at 4 or 25 degrees C for one week, hemoglobin, lipoproteins, or corticosteroid medications. Bilirubin, at concentrations of 20 mg/L of serum or move, significantly inhibited the assay. Sera with increased activity showed nonlinear reaction rates during the usual 60-min reaction interval, This was corrected by shortening the reaction time to 30 min. We found a predictive value of 88% when the serum angiotensin converting enzyme test was applied to the diagnosis of active sarcoidosis.


2008 ◽  
Vol 47 (06) ◽  
pp. 235-238 ◽  
Author(s):  
M. Dietlein ◽  
C. Mauz-Körholz ◽  
A. Engert ◽  
P. Borchmann ◽  
O. Sabri ◽  
...  

SummaryThe high negative predictive value of FDG-PET in therapy control of Hodgkin lymphoma is proven by the data acquired up to now. Thus, the analysis of the HD15 trial has shown that consolidation radiotherapy might be omitted in PET negative patients after effective chemotherapy. Further response adapted therapy guided by PET seems to be a promising approach in reducing the toxicity for patients undergoing chemotherapy. The criteria used for the PET interpretation have been standardized by the German study groups for Hodgkin lymphoma patients and will be reevaluated in the current studies.


Sign in / Sign up

Export Citation Format

Share Document